Reply to the Commentary on the article “Sepsis in children: federal guidelines (draft)” I.А. Savin

Abstract

The authors of the Clinical Guidelines are grateful to Professor I.A. Savin for his comments and provide answers to the comments made regarding the appointment of antibacterial drugs and immunoglobulins for sepsis in children.

Keywords

sepsis / clinical guidelines / children

References

[1] Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management Sepsis and Septic Shock and Sepsis-associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21(2):e52–e106. DOI: 10.1097/PCC.0000000000002198

[2] Weiss S.L., Peters M.J., Alhazzani W., et al. Surviving Sepsis Campaign International Guidelines for the Management Sepsis and Septic Shock and Sepsis-associated Organ Dysfunction in Children // Pediatr Crit Care Med. 2020. Vol. 21. No. 2. P. e52–e106. DOI: 10.1097/PCC.0000000000002198

[3] El-Nawawy A, El-Kinany H, Hamdy El-Sayed M, Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit. J Trop Pediatr. 2005;51(5):271-278. DOI: 10.1093/tropej/fmi011

[4] El-Nawawy A., El-Kinany H., Hamdy El-Sayed M., Boshra N. Intravenous polyclonal immunoglobulin administration to sepsis syndrome patients: a prospective study in a pediatric intensive care unit // J Trop Pediatr. 2005. Vol. 51. No. 5. P. 271–278. DOI: 10.1093/tropej/fmi011

[5] Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates. Cochrane Database Syst Rev. 2013;(7):CD001239. DOI: 10.1002/14651858.CD001239.pub4. Corrected and republished from: Cochrane Database Syst Rev. 2015;(3):CD001239. DOI: 10.1002/14651858.CD001239.pub5

[6] Ohlsson A., Lacy J.B. Intravenous immunoglobulin for suspected or proven infection in neonates // Cochrane Database Syst Rev. 2013. Vol. 2. No. 7. P. CD001239. DOI: 10.1002/14651858.CD001239.pub4. Corrected and republished from: Cochrane Database Syst Rev. 2015. No. 3. P. CD001239. DOI: 10.1002/14651858.CD001239.pub5

[7] INIS Collaborative Group; Brocklehurst P, Farrell B, King A, et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med. 2011;365(13):1201–1211. DOI: 10.1056/NEJMoa1100441

[8] INIS Collaborative Group; Brocklehurst P., Farrell B., King A., et al. Treatment of neonatal sepsis with intravenous immune globulin // N Engl J Med. 2011. Vol. 29, No. 365(13). P. 1201–1211. DOI: 10.1056/NEJMoa1100441

[9] Beloborodova NV, Popov DA, Shatalov KV, et al. Zamestitel’naja immunoterapija pod kontrolem testa na prokal’citonin – novyj podhod k preduprezhdeniju manifestacii infekcii v posleoperacionnom periode u detej so slozhnymi vrozhdennymi porokami serdca. Heart and Vessels Diseases in Children. 2005;3:62–68. (In Russ.)

[10] Белобородова Н.В., Попов Д.А., Шаталов К.В., и др. Заместительная иммунотерапия под контролем теста на прокальцитонин — новый подход к предупреждению манифестации инфекции в послеоперационном периоде у детей со сложными врожденными пороками сердца // Детские болезни сердца и сосудов. 2005. Т. 3. С. 62–68.

[11] Abdullayev E, Kilic O, Bozan G, et al. Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study). Human Vaccines & Immunotherapeutics. 2020;16(8):1997–2002. DOI: 10.1080/21645515.2019.1711298

[12] Abdullayev E., Kilic O., Bozan G., et al. Clinical, laboratory features and prognosis of children receiving IgM-enriched immunoglobulin (3 days vs. 5 days) as adjuvant treatment for serious infectious disease in pediatric intensive care unit: a retrospective single-center experience (PIGMENT study). Human Vaccines & Immunotherapeutics. 2020. Vol. 16. No. 8. P. 1997–2002. DOI: 10.1080/21645515.2019.1711298

[13] Martinez J-I, Sánchez H-F, Velandia J-A, et al. Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis. J Crit Care. 2021;64:120–124. DOI: 10.1016/j.jcrc.2021.03.015

[14] Martinez J.-I., Sánchez H.-F., Velandia J.-A., et al. Treatment with IgM-enriched immunoglobulin in sepsis: a matched case-control analysis // J Crit Care. 2021. Vol. 64. P. 120–124. DOI: 10.1016/j.jcrc.2021.03.015

RIGHTS & PERMISSIONS

Lekmanov A.U., Popov D.А.